AKTIV-DRY’s experts have a proven track record in micronizing and drying vaccines, antibodies, enzymes, proteins and other pharmaceutical compounds.

AKTIV-DRY engineers particle sizes and morphology to satisfy your requirements.

AKTIV-DRY is a spin-out company formed by University of Colorado Professors Bob Sievers and John Carpenter, and Dr. Brian Quinn to commercialize innovations in particle synthesis and coating.

Deliver aerosols of fine respirable powders to mucosa where infections can be prevented or cured.

Higher concentrations can be delivered to sites where needed and persist longer than with needle injections.

Disease transmission by needles and accidental pricks can be avoided.

Room temperature stabilized dry powders of measles vaccine delivered in aerosol form to the lungs and/or nasal passages may be patterned after influenza vaccines.

Bioavailabity of drugs can be optimized by manufacture of microparticles and nanoparticles.